ClinicalTrials.gg
RecruitingNCT06651684CanCEASE-2Updated Jul 24, 2026

Smoking Cessation Intervention Including Health Navigators to Address Unmet Social Needs of Parents Who Smoke

An interventional study of CanCEASE with Health Navigator in Smoking Cessation and Tobacco Dependence, sponsored by St. Justine's Hospital. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by St. Justine's Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background: The goal of this study is to address parental smoking and social adversity, which can present an obstacle for smoking cessation, in order to decrease childhood exposure to second-hand cigarette smoke. To address these factors, this study includes a smoking cessation intervention for parents and legal guardians recruited in pediatric clinics (CanCEASE), as well as the support of a Health Navigator (HN) to work with the participant towards the resolution or mitigation of unmet social needs.

Participants: The research team will recruit one thousand participants from pediatric outpatient clinics within two healthcare centres in and around the city of Montreal, Canada, over the course of 2.5 years. Eligible persons are parents and legal guardians, of any sex and gender, accompanying children under 18 to their scheduled medical appointments, and who report at least one social risk in selected areas (i.e., employment, housing stability, ability to pay for utilities, financial resource strain, food security, transportation, childcare, parent education and health literacy). Participants must also be 18 years old or older with sufficient proficiency in French or English to complete the interviews and questionnaires. In households in which both parents smoke, only one will be eligible to participate, but smoking cessation information will be offered to both. Families presenting at the clinic for an urgent medical issue are not eligible to participate.

Intervention: Participants will be divided into control group (care as usual with CanCEASE at the end of the study period) and intervention (CanCEASE + Health navigator). All participants will complete questionnaires at Baseline, 6 and 12 months. The intervention group will receive CanCEASE at the end of each questionnaire. Controls will receive CanCEASE at 12 months. The intervention group will have the possibility to meet with the HNs and will be invited to commit to at least two sessions (i.e.: evaluation and a follow up), with the option to book more time as needed.

Aims and hypotheses: Examining how effective the combination of CanCEASE with HN support is in helping parents with unmet social needs quit smoking. Investigators will also examine the effects of the intervention on status of unmet social needs, if the intervention was implemented as planned and well accepted by clinics and participants, and what is the cost of the intervention for each person who quits smoking.

Read the detailed description

Primary purpose: The overarching goal of the study is to address child second-hand-smoke exposure by supporting parent smoking cessation. For that purpose, the investigators designed the present investigator-blinded, randomized controlled clinical trial, to be carried out in real-world settings, in order to test the effectiveness of two combined interventions, one to promote smoking cessation and another to support parents with unmet social needs, which could be hindering their smoking cessation efforts.

Rationale: In Canada, tobacco use is the greatest cause of preventable morbidity and mortality, generating attributable annual health-related costs of CAD $16.2 billion and 48 thousand deaths. Parental smoking has direct impacts on child health, starting at in-utero stages (e.g., fetal growth restriction, premature birth, sudden infant death syndrome, and exacerbation of respiratory illnesses) and it contributes to child and adolescent smoking initiation. Yet, despite its well-known negative effects, 15% of Canadian children are exposed to household second-hand smoke. Data also indicate that parents are overall underserved in terms of medical care and see their child(ren)'s medical care providers more often than their own, but they are not frequently screened for smoking (less than 5% of visits to pediatric practices) nor do they receive any smoking cessation support. Yet, twenty-five percent of all adult smokers have children who are seen in child healthcare offices. Further, smoking and social economic status (SES) are strongly associated, such that populations with lower SES present higher proportions of tobacco use, indicating lower SES can be an obstacle to smoking cessation as well as a perpetuating factor for smoking.

Aims and hypotheses:

Aim 1 - Examining the effectiveness of the intervention (CanCEASE + HN) on smoking cessation compared to care-as-usual. Hypothesis 1: the intervention will lead to a higher proportion of quits among smoking parents than the control condition.

Aim 2 - Examining the effectiveness of the intervention (HN) on unmet social needs and, if so, does the resolution of an unmet social need mediate CanCEASE-related smoking cessation. Hypotheses: (2a) there will be a greater decrease in the prevalence of unmet social needs in the intervention vs. control arm; (2b) resolution of unmet social need(s) will mediate in part the effect of the intervention on smoking cessation.

Aim 3 - Assessing whether the intervention (CanCEASE + HN) implemented as planned is acceptable to participants and practices. Hypotheses: (3a) both intervention and control will be acceptable to participants and practices where they are implemented; (3b) both the intervention and control will be delivered as planned to most participants.

Aim 4 - Examining the incremental cost-effectiveness ratio in Canadian dollars per quit of CanCEASE with HN compared to care-as-usual. Hypothesis 4: The intervention will have a favorable cost per quit compared to control.

Participant recruitment: Participants (N=1000) will be recruited from pediatric outpatient clinics in two healthcare centres in Montreal, Canada (i.e., General pediatrics outpatient clinic, CHU Sainte-Justine; Outpatient pediatric clinics, Hôpital Maisonneuve-Rosemont). Potential participants will initially undergo a brief pre-screening process that should take under a minute to complete. It is designed for initial identification of parents who smoke using questions about data on relationship of the child with the accompanying adult, smoking status of the adult and contact information. This first pass prevents adults in the clinic from spending too much time in activities unrelated to their visit and prevents disruption of the work flow at the recruiting sites. Pre-screening can be completed via the study website, self-check-in stations in the recruitment sites (where available), and via the hospital appointment confirmation systems. Alternatively, pre-screening will be conducted by an on-site research assistant when parents come to register for an appointment. Recruitment will also be done via referral by the clinical or front desk teams either by having interested individuals fill out an "authorization to contact form" or by scanning a QR code from posters that will be placed in the clinics, such that the research team can contact potential participants to present the study, obtain informed consent, assess them for social risks to determine if the individual is eligible to participate in the study.

Intervention: CanCEASE is a parental smoking cessation intervention that facilitates referral and linkage to existing healthcare and community resources and it is available in both French and English. It consists of (1) asking about smoking status, (2) a self-assessment of readiness to quit, and interest in available resources, (3) providing advice on available services with brief motivational messages, (4) assistance to quit, via quit lines and text message support, and (5) assistance with access to Nicotine Replacement Therapy (NRT). Participants will be randomized either to the control or the intervention arm of the study. In both arms, participants will complete three questionnaires, one within the first month after recruitment, then 6 and 12 months later. CanCEASE will be offered after the end of each questionnaire to participants in the intervention arm of the study and after the 12-month questionnaire to control participants. Control group will receive care-as-usual, depending on what is typically available on site, and at recruitment, a resource list with freely available cessation resources with advice on how to obtain NRT. Participants in the intervention group will receive, in addition to CanCEASE, two support sessions a health navigator (HN). HNs are individuals trained in specific areas of health, but who do not necessarily hold a professional degree. Their role is to provide assistance in ways that are complementary to what an individual receives from the healthcare system. HNs can potentially enhance smoking cessation efforts by facilitating access to resources and supporting participants facing poverty-related challenges that hinder their cessation efforts. Participants are expected to commit to at least two sessions with the HN, the initial evaluation and follow up. Session 1 will take place about 14 days after baseline questionnaire, according to participant availability. It will consist of an evaluation, information session, specification of quitting goals and specifying unmet social needs. During and, if needed, on the days following the session, the HN will facilitate participant access to resources and send support materials as needed. Session 2 will occur about a month after baseline questionnaire, according to participant availability. At this time, the HN will go over the current smoking and unmet needs status, inquire about barriers and challenges, and will follow-up on referrals and resources that were previously provided. Participants are free to book additional HN sessions as needed for as long as they are actively taking part in the study. After every session, participants will receive a satisfaction survey to fill out. Whenever a participant reports having quit smoking, they will be invited to provide a urine sample for lab confirmation that there is no longer any nicotine in their system. Urine samples will be self-collected and sent by accelerated postage.

Relevance: This RCT will compare, in families with unmet social needs, the effectiveness and cost-effectiveness of the CanCEASE intervention for parental smoking cessation with HN support in comparison to care as usual plus information on freely available cessation resources. It could yield data that supports leveraging implementation of preventive primary care to improve population health.

02

Conditions studied

  • Smoking Cessation
  • Tobacco Dependence

Keywords

  • Smoking cessation
  • Social risk
  • Second hand smoke
  • Health navigator
  • Unmet social needs
03

In context

Smoking Cessation

1,581 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 164 across 1,423 interventional studies indexed under Smoking Cessation.

Browse Smoking Cessation studies →

Lead sponsor

St. Justine's Hospital is the lead sponsor of 156 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parents or legal guardians aged ≥18 years, with child(ren) aged 0-17 years, attending a regular scheduled medical appointment in one of the study sites.
  • Pregnant patients aged ≥18 years who are parents or legal guardians of child(ren) aged 0-17 years coming in for an prenatal appointment.
  • Smokers with at least one self-reported social risk as assessed by validated screening questions on the domains employment, housing stability, ability to pay for utilities, financial resource strain, food security, transportation, childcare, parent education and health literacy.
  • Sufficiently proficient in French or English to understand and complete study questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Families presenting at the clinic for an urgent medical issue.
  • Parents without at least one social risk.
  • If both parents smoke, only one parent will be eligible to participate.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
1,000 participants (estimated)

Study arms

  • No intervention
    Care-as-usual

    Participants assigned to this group will receive care as usually delivered in participating clinics and list of smoking cessation resources, including instructions to access Nicotine Replacement Therapy (NRT).

  • Experimental
    CanCEASE with Health Navigator

    Participants assigned to this arm will receive smoking cessation resources, including instructions to access Nicotine Replacement Therapy (NRT) at Baseline, 6 and 12 months. They will also have the choice to schedule support sessions with a Health Navigator, which will be an individual with lived experience related to tobacco and trained to provide support for unmet social needs.

    Behavioral: CanCEASE with Health Navigator

Interventions

  • BehavioralCanCEASE with Health Navigator

    CanCEASE is a digital intervention to identify parents who smoke, assess their motivation and willingness to quit, as well as to provide direct linkage to evidence-based smoking interventions, including effective behavioural and pharmacological resources that can be used alone or in combination. Participants will have the choice to receive CanCEASE at three timepoints (0, 6 and 12 months). CanCEASE will be combined with an offer of support sessions with a Health Navigator. Health Navigators will be research personnel hired specifically for this study and trained formally in health navigation, tobacco cessation counseling and strategies to address unmet social needs. The investigators will leverage knowledge and experience of two ongoing RCTs of HNs in pediatrics to inform training strategies.

06

What researchers measure

Primary outcomes

  1. Aim 1 - 7-day abstinence

    Percentage of participants who self-report 7-day abstinence

    Time frame: 6 months; 12 months

  2. Aim 1 - Smoking intensity

    Average self-reported number of cigarettes per day.

    Time frame: 0 months; 6 months; 12 months

  3. Aim 1 - Cotinine-confirmed quit

    Urinary cotinine values below 100 ng/ml, a consensus cutoff level, biochemical confirmation of 7-day abstinence.

    Time frame: 6 months; 12 months

  4. Aim 1 - Anabasine-confirmed quit

    Urinary anabasine detection allows for the differentiation between smokers and abstainers who are using NRT at concentrations below 1.2 ng/mL.

    Time frame: 6 months; 12 months

  5. Aim 1 - Quit attempts

    Percentage of participants who report at least one 24-hour quit.

    Time frame: 6 months; 12 months

  6. Aim 1 - Intent to quit

    Percentage of parental smokers who are seriously considering quitting in the next six months.

    Time frame: 0 months; 6 months; 12 months

  7. Aim 2 - Resolution of social risk

    Percentage of participants who report resolution of one or more social risks at the end of the study. Outcome will be calculated via the comparison of Social Risk questionnaire responses at baseline and at 12 months to determine persistence of social risk (no longer reported=yes; still reported=no).

    Time frame: 12 months

  8. Aim 2 - Improvement in unmet social needs

    Self-reported improvement in unmet social need present at baseline on a 5-point Likert scale wherein: 1=Much better, 2=Somewhat better, 3=Stayed the same, 4=Somewhat worse, 5=Much worse.

    Time frame: 12 months

  9. Aim 2 - Access to resources to help with unmet social needs

    Percentage of participants who, at follow-up, self-report having accessed 1+ resources for each unmet social needs present at baseline

    Time frame: 12 months

  10. Aim 3 - Interest in resources to help them quit

    Percentage of participants who are interested in referral to quitline or text-message cessation program (SMAT) and/or prescription of pharmacotherapy to help quit (NRT)

    Time frame: 0 months; 6 months; 12 months

  11. Aim 3 - Meaningful receipt of assistance

    Percentage of participants who, at follow-up, self-report having received at least one of the following: referral to quitline or text-message cessation program (SMAT) or prescription of pharmacotherapy to help quit (NRT).

    Time frame: 6 months; 12 months

  12. Aim 3 - Proportion or participants who had contact with HNs

    Percentage of participants who, at follow-up, self-report having received at least one session with health navigator (Intervention arm only)

    Time frame: 12 months

  13. Aim 3 - Number of sessions with heath navigators

    For each participant, number of sessions with the health navigator (Intervention arm only).

    Time frame: 12 months

  14. Aim 3 - Duration of sessions with heath navigators (in minutes)

    For each participant, the average number of minutes per session health navigators spent with participants on average (Intervention arm only).

    Time frame: 12 months

  15. Aim 4 - Incremental cost-effectiveness ratio - intervention vs. usual care (from a healthcare system perspective)

    Difference in costs (intervention minus control) divided by difference in effectiveness (intervention minus control). Reported in Canadian dollars per quit. Costs will include both material and personnel costs. Personnel costs will be obtained by multiplying the total time devoted to interventions/usual care activities by national average wage rate for each type of personnel.

    Time frame: Through study completion, an average of 1 year

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2029, 35 months after the start.

Of 546 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 35 months is above that.

Counting every sponsor, half of 563 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2024
First posted
Oct 22, 2024
StartActual
Mar 26, 2026
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2030
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06651684
Responsible party
Olivier Drouin, M.D., M.Sc M.P.H. (Pediatrician and Clinical Assistant Professor, Departments of Paediatrics and Department of Social and Preventive Medicine, St. Justine's Hospital) — Principal investigator
First posted
Oct 22, 2024
Start date
Mar 26, 2026
Primary completion
Feb 2029 (estimated)
Completion
Feb 2030 (estimated)
Last update
Jul 24, 2026

Study contacts

Melissa Nicolosi, B.A.
Contact
melissa.nogueira.nicolosi.hsj@ssss.gouv.qc.ca
(514) 345-4931 ext. 117371
Tamara Perez, MSc
Contact
tamara.perez.hsj@ssss.gouv.qc.ca
514 834-0212
Olivier Drouin, MD, MSc, MPH
principal investigator · CHU Sainte-Justine Research Centre
Nicholas Chadi, MD, MPH
principal investigator · CHU Sainte-Justine Research Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion